Similar articles

• Ticlopidine as an experimental antithrombotic agent.

  Vallée E, Maffrand JP, Bernat A, Delebassée D, Tissinier A. Vallée E, et al. Agents Actions Suppl. 1984;15:50-9. doi: 10.1007/BF01966961. Agents Actions Suppl. 1984. PMID: 6592945 No abstract available.
• Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.

  de Gaetano G, Bertelé V. de Gaetano G, et al. Arq Bras Cardiol. 1983 Dec;41(6):425-7. Arq Bras Cardiol. 1983. PMID: 6678584 No abstract available.
• Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function.

  Picard-Fraire C. Picard-Fraire C. Agents Actions Suppl. 1984;15:68-75. Agents Actions Suppl. 1984. PMID: 6385655 Review. No abstract available.
• [Evaluation of platelet aggregation in patients treated with ticlopidine].

  Sbalzarini G, Carniti E, Fiorini L, Iezzi BG. Sbalzarini G, et al. Clin Ter. 1984 Nov 15;111(3):247-50. Clin Ter. 1984. PMID: 6240365 Italian. No abstract available.
• Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function.

  Picard-Fraire C. Picard-Fraire C. Thromb Res Suppl. 1983;4:119-28. doi: 10.1016/0049-3848(83)90367-5. Thromb Res Suppl. 1983. PMID: 6356462 Review.